ticlopidine has been researched along with Neutropenia in 50 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Ticlopidine Microangiopathy of Diabetes study (TIMAD), a randomized, double-masked, placebo-controlled trial, assessed the effect of this antiplatelet agent (ticlopidine hydrochloride) in reducing the progression of nonproliferative diabetic retinopathy in 435 patients followed up for 3 years." | 9.06 | Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. ( , 1990) |
| "We report a case of ticlopidine-induced profound neutropenia early in the course of therapy, which was manifest as a febrile systemic illness mimicking sepsis." | 8.80 | Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. ( Lenihan, DJ; Lewis, P; Ochoa, AB; Wolfe, M, 1998) |
| " We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor." | 7.81 | Ticagrelor as an alternative in clopidogrel-associated neutropenia. ( Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R, 2015) |
| "Authors describe a case of neutropenia induced by ticlopidine." | 7.75 | [Neutropenia induced by ticlopidine: a delayed onset case]. ( Bellarosa, I; Nargi, L; Orlando, V; Scarano, V; Terracciano, AM, 2009) |
| "We report a case of a severe hypersensitivity syndrome reaction to clopidogrel that resolved with dechallenge and recurred on rechallenge." | 7.73 | Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. ( Begg, EJ; Bridgman, P; Doogue, MP, 2005) |
| "We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 7.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
| "To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug." | 7.69 | Delayed neutropenia with ticlopidine. ( Farver, DK; Hansen, LA, 1994) |
| "Healthcare professionals must be aware of the possibility of severe neutropenia and death caused by ticlopidine, even when the manufacturers' monitoring guidelines are followed." | 7.69 | Fatal neutropenia and thrombocytopenia associated with ticlopidine. ( Carlson, JA; Maesner, JE, 1994) |
| "An 83-year-old white man developed febrile neutropenia 5 days after initiation of ticlopidine therapy." | 7.69 | Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia. ( Geletko, SM; Melbourne, KM; Mikolich, DJ, 1996) |
| "to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials." | 5.51 | Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019) |
| "Neutropenia is a significant adverse effect and pancytopenia is rarely reported." | 5.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| "Ticlopidine (TCP) is a drug that inhibits platelet aggregation." | 5.29 | [Ticlopidine-induced neutropenia]. ( Atias, D; Balbir, A; Odeh, M; Oliven, A, 1996) |
| "In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure." | 5.09 | Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999) |
| " Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "The Ticlopidine Microangiopathy of Diabetes study (TIMAD), a randomized, double-masked, placebo-controlled trial, assessed the effect of this antiplatelet agent (ticlopidine hydrochloride) in reducing the progression of nonproliferative diabetic retinopathy in 435 patients followed up for 3 years." | 5.06 | Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. ( , 1990) |
| "We report a case of ticlopidine-induced profound neutropenia early in the course of therapy, which was manifest as a febrile systemic illness mimicking sepsis." | 4.80 | Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. ( Lenihan, DJ; Lewis, P; Ochoa, AB; Wolfe, M, 1998) |
| "Several rare, potentially fatal types of hematologic dyscrasia, such as agranulocytosis, aplastic anemia, neutropenia, pancytopenia, thrombocytopenia and thrombotic thrombocytopenic purpura (TTP), have been associated with ticlopidine therapy." | 4.80 | Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. ( Angelo, CM; Cohen, EA; Lanctôt, KL; Paradiso-Hardy, FL, 2000) |
| " We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor." | 3.81 | Ticagrelor as an alternative in clopidogrel-associated neutropenia. ( Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R, 2015) |
| "We report a case of a severe hypersensitivity syndrome reaction to clopidogrel that resolved with dechallenge and recurred on rechallenge." | 3.73 | Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. ( Begg, EJ; Bridgman, P; Doogue, MP, 2005) |
| " The patient evolved with neutropenia induced by ticlopidine after 10 days of treatment." | 3.71 | Fibroelastoma of the mitral valve as a cause of transient ischemic stroke. ( Alessi, A; Bertolin Précoma, D; Fontoura, D; Gomes de Carvalho, R; Oliveira, LR; Zanis Neto, J; Zapparoli, M, 2001) |
| "We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 3.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
| "To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug." | 3.69 | Delayed neutropenia with ticlopidine. ( Farver, DK; Hansen, LA, 1994) |
| "Healthcare professionals must be aware of the possibility of severe neutropenia and death caused by ticlopidine, even when the manufacturers' monitoring guidelines are followed." | 3.69 | Fatal neutropenia and thrombocytopenia associated with ticlopidine. ( Carlson, JA; Maesner, JE, 1994) |
| "An 83-year-old white man developed febrile neutropenia 5 days after initiation of ticlopidine therapy." | 3.69 | Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia. ( Geletko, SM; Melbourne, KM; Mikolich, DJ, 1996) |
| "048), and the frequency of adverse events was not significantly different between the two treatment groups." | 2.67 | The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. ( Weisberg, LA, 1993) |
| "Ticlopidine has not been formally compared with aspirin in patients with a completed stroke." | 2.67 | Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. ( Harbison, JW, 1992) |
| "Agranulocytosis is a life-threatening disorder that frequently occurs as an adverse reaction to drugs." | 2.43 | [Idiosyncratic drug-induced agranulocytosis]. ( Andrès, E; Maloisel, F, 2006) |
| "Ticlopidine is an antiplatelet agent that is used to reduce the occurrence of atherothrombotic arterial events." | 2.40 | Adverse haematological effects of ticlopidine. Prevention, recognition and management. ( Biller, J; Gent, M; Love, BB, 1998) |
| "Ticlopidine was first shown to decrease major events compared with placebo or aspirin in patients with stroke or recent transient ischemic attack." | 2.40 | The antiplatelet effects of ticlopidine and clopidogrel. ( Cannon, CP; Loscalzo, J; Sharis, PJ, 1998) |
| "to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials." | 1.51 | Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study. ( Bae, HJ; Jeong, HG; Lee, J; Yoon, JS, 2019) |
| "Neutropenia is a significant adverse effect and pancytopenia is rarely reported." | 1.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| "Ticlopidine (TCP) is a drug that inhibits platelet aggregation." | 1.29 | [Ticlopidine-induced neutropenia]. ( Atias, D; Balbir, A; Odeh, M; Oliven, A, 1996) |
| "In 2 ticlopidine was the only medication taken before TTP; in another, rechallenge with drugs other than ticlopidine that the patient had been taking did not produce relapse." | 1.28 | Thrombotic thrombocytopenic purpura related to ticlopidine. ( Bertrand, JC; Comtet, C; Page, Y; Tardy, B; Terrana, R; Zeni, F, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.00) | 18.7374 |
| 1990's | 29 (58.00) | 18.2507 |
| 2000's | 15 (30.00) | 29.6817 |
| 2010's | 3 (6.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, HG | 1 |
| Yoon, JS | 1 |
| Lee, J | 1 |
| Bae, HJ | 1 |
| Shah, R | 1 |
| Keough, LA | 1 |
| Belalcazar-Portacio, A | 1 |
| Ramanathan, KB | 1 |
| Bellarosa, I | 1 |
| Nargi, L | 1 |
| Scarano, V | 1 |
| Terracciano, AM | 1 |
| Orlando, V | 1 |
| Lokhandwala, JO | 1 |
| Best, PJ | 1 |
| Butterfield, JH | 1 |
| Skelding, KA | 1 |
| Scott, T | 1 |
| Blankenship, JC | 1 |
| Buckley, JW | 1 |
| Berger, PB | 2 |
| Uz, O | 1 |
| Kardeşoğlu, E | 1 |
| Aparci, M | 1 |
| Yiğiner, O | 1 |
| Işilak, Z | 1 |
| Ozmen, N | 1 |
| de la Torre Lima, FJ | 1 |
| Prada Parda, JL | 1 |
| López López, R | 1 |
| del Arco Jiménez, A | 1 |
| Akcay, A | 1 |
| Kanbay, M | 1 |
| Agca, E | 1 |
| Sezer, S | 1 |
| Ozdemir, FN | 1 |
| Andrès, E | 1 |
| Maloisel, F | 1 |
| Doogue, MP | 1 |
| Begg, EJ | 1 |
| Bridgman, P | 1 |
| Suh, SY | 1 |
| Rha, SW | 1 |
| Kim, JW | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Ro, YM | 1 |
| Vendrametto, F | 1 |
| Pitscheider, W | 1 |
| Oberhollenzer, R | 1 |
| Moretti, M | 1 |
| Nicolosi, GL | 1 |
| Schäfer, A | 1 |
| Eigenthaler, M | 1 |
| Bauersachs, J | 1 |
| Goyan, JE | 1 |
| Ruiz-Irastorza, G | 1 |
| Alonso, JJ | 1 |
| Iglesias, JJ | 1 |
| Aguirre, C | 1 |
| Farver, DK | 1 |
| Hansen, LA | 1 |
| Carlson, JA | 1 |
| Maesner, JE | 1 |
| Oster, G | 1 |
| Huse, DM | 1 |
| Lacey, MJ | 1 |
| Epstein, AM | 1 |
| Weisberg, LA | 1 |
| Geletko, SM | 1 |
| Melbourne, KM | 1 |
| Mikolich, DJ | 1 |
| Schöneberger, AA | 1 |
| Schmidt, K | 1 |
| Balbir, A | 1 |
| Odeh, M | 1 |
| Atias, D | 1 |
| Oliven, A | 1 |
| Haushofer, A | 1 |
| Halbmayer, WM | 1 |
| Prachar, H | 1 |
| Neumann, FJ | 1 |
| Hall, D | 1 |
| Schömig, A | 1 |
| Gill, S | 1 |
| Majumdar, S | 1 |
| Brown, NE | 1 |
| Armstrong, PW | 1 |
| Thomson, LE | 1 |
| Stewart, JT | 1 |
| Ochoa, AB | 1 |
| Wolfe, M | 1 |
| Lewis, P | 1 |
| Lenihan, DJ | 1 |
| Gur, H | 1 |
| Wartenfeld, R | 1 |
| Tanne, D | 1 |
| Solomon, F | 1 |
| Sidi, Y | 1 |
| Love, BB | 1 |
| Biller, J | 1 |
| Gent, M | 2 |
| Sharis, PJ | 1 |
| Cannon, CP | 1 |
| Loscalzo, J | 1 |
| Korkmaz, ME | 1 |
| Cekin, AH | 1 |
| Bell, MR | 1 |
| Hasdai, D | 1 |
| Grill, DE | 1 |
| Melby, S | 1 |
| Holmes, DR | 1 |
| Szto, GY | 1 |
| Linnemeier, TJ | 1 |
| Ball, MW | 1 |
| Moussa, I | 1 |
| Oetgen, M | 1 |
| Roubin, G | 1 |
| Colombo, A | 1 |
| Wang, X | 1 |
| Iyer, S | 1 |
| Maida, R | 1 |
| Collins, M | 1 |
| Kreps, E | 1 |
| Moses, JW | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Dieter, RS | 2 |
| Diener, HC | 1 |
| Paradiso-Hardy, FL | 1 |
| Angelo, CM | 1 |
| Lanctôt, KL | 1 |
| Cohen, EA | 1 |
| Taniuchi, M | 1 |
| Kurz, HI | 1 |
| Lasala, JM | 1 |
| Alessi, A | 1 |
| Gomes de Carvalho, R | 1 |
| Bertolin Précoma, D | 1 |
| Fontoura, D | 1 |
| Oliveira, LR | 1 |
| Zanis Neto, J | 1 |
| Zapparoli, M | 1 |
| Martínez Ruiz, M | 1 |
| Llobell Segui, G | 1 |
| Peralba Vaño, JI | 1 |
| Toral Revuelta, JR | 1 |
| Mellado del Rey, F | 1 |
| González de Aledo, GB | 1 |
| Harbison, JW | 1 |
| Haynes, RB | 1 |
| Sandler, RS | 1 |
| Larson, EB | 1 |
| Pater, JL | 1 |
| Yatsu, FM | 1 |
| Page, Y | 1 |
| Tardy, B | 1 |
| Zeni, F | 1 |
| Comtet, C | 1 |
| Terrana, R | 1 |
| Bertrand, JC | 1 |
| Martín Casellas, E | 1 |
| Bosch Llobet, A | 1 |
| Tous Quintana, R | 1 |
| FitzGerald, GA | 1 |
| Merz, B | 1 |
| Montanari, G | 1 |
| Mussida, M | 1 |
| Scarabelli, C | 1 |
| Zinzalini, G | 1 |
7 reviews available for ticlopidine and Neutropenia
| Article | Year |
|---|---|
[Idiosyncratic drug-induced agranulocytosis].
Topics: Agranulocytosis; Anti-Bacterial Agents; Antithyroid Agents; Diagnosis, Differential; Fever; Fibrinol | 2006 |
Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Granulocyte Colony-Stimulating Factor; Humans; Male; Neutropenia; Re | 1994 |
Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement.
Topics: Coronary Angiography; Coronary Disease; Diagnosis, Differential; Female; Follow-Up Studies; Humans; | 1998 |
Adverse haematological effects of ticlopidine. Prevention, recognition and management.
Topics: Anemia, Aplastic; Cerebrovascular Disorders; Female; Humans; Male; Neutropenia; Platelet Aggregation | 1998 |
The antiplatelet effects of ticlopidine and clopidogrel.
Topics: Cardiovascular Diseases; Clopidogrel; Drug Costs; Female; Humans; Male; Neutropenia; Platelet Aggreg | 1998 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
Topics: Bayes Theorem; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Male; Neutrop | 2000 |
8 trials available for ticlopidine and Neutropenia
| Article | Year |
|---|---|
The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Stu | 1993 |
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra | 1999 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; | 2001 |
Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Diarrhea; Double-Blind Method; Female; Humans; Male; Midd | 1992 |
Ticlopidine in unstable angina. A more expensive aspirin?
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Cycloox | 1990 |
Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group.
Topics: Adolescent; Adult; Aged; Diabetic Angiopathies; Diabetic Retinopathy; Diarrhea; Double-Blind Method; | 1990 |
35 other studies available for ticlopidine and Neutropenia
| Article | Year |
|---|---|
Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study.
Topics: Aged; Cohort Studies; Drug Combinations; Female; Ginkgo biloba; Hemorrhage; Humans; Incidence; Male; | 2019 |
Ticagrelor as an alternative in clopidogrel-associated neutropenia.
Topics: Acute Coronary Syndrome; Adenosine; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; | 2015 |
[Neutropenia induced by ticlopidine: a delayed onset case].
Topics: Aged; Female; Humans; Neutropenia; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2009 |
Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel.
Topics: Aged; Angioedema; Clopidogrel; Drug Hypersensitivity; Exanthema; Female; Humans; Male; Neutropenia; | 2009 |
Nonfatal aplastic anemia associated with clopidogrel.
Topics: Anemia, Aplastic; Clopidogrel; Coronary Vessels; Humans; Male; Middle Aged; Neutropenia; Pancytopeni | 2010 |
[Severe neutropenia induced by ticlopidine. Presentation of two cases and review of the literature].
Topics: Aged; Fatal Outcome; Female; Humans; Male; Neutropenia; Opportunistic Infections; Platelet Aggregati | 2002 |
Neutropenia due to clopidogrel in a patient with end-stage renal disease.
Topics: Adult; Clopidogrel; Humans; Kidney Failure, Chronic; Male; Neutropenia; Platelet Aggregation Inhibit | 2004 |
Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Hypersensitivity; Female; | 2005 |
Neutropenia associated with clopidogrel use in a patient with chronic renal failure who underwent percutaneous coronary and peripheral intervention.
Topics: Adult; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clopidogrel; Fatal Outcome; Female; Gra | 2006 |
[Can clopidogrel be responsible for neutropenia?].
Topics: Aged, 80 and over; Clopidogrel; Female; Humans; Neutropenia; Platelet Aggregation Inhibitors; Ticlop | 2006 |
Severe neutropenia under clopidogrel treatment three weeks after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fem | 2007 |
Ticlopidine: quo vadis? Adverse reactions in man.
Topics: Anticoagulants; Aspirin; Diarrhea; Humans; Neutropenia; Product Surveillance, Postmarketing; Thiophe | 1984 |
Delayed neutropenia with ticlopidine.
Topics: Aged; Blood Cell Count; Female; Humans; Ischemic Attack, Transient; Neutropenia; Pneumonia; Ticlopid | 1994 |
Fatal neutropenia and thrombocytopenia associated with ticlopidine.
Topics: Aged; Aged, 80 and over; Fatal Outcome; Humans; Male; Neutropenia; Thrombocytopenia; Ticlopidine | 1994 |
Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cohort Studies; Cost-Benefit Analysis; Decision Support Te | 1994 |
Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Cephalosporins; Filgrastim; | 1996 |
Antiplatelet and anticoagulant therapy after coronary-artery stenting.
Topics: Aged; Coronary Disease; Humans; Male; Neutropenia; Platelet Aggregation Inhibitors; Stents; Ticlopid | 1996 |
[Ticlopidine-induced neutropenia].
Topics: Aged; Aged, 80 and over; Blood Cell Count; Cerebrovascular Disorders; Female; Humans; Male; Neutrope | 1996 |
Neutropenia with ticlopidine plus aspirin.
Topics: Agranulocytosis; Aspirin; Coronary Disease; Humans; Monitoring, Physiologic; Neutropenia; Platelet A | 1997 |
Neutropenia with ticlopidine plus aspirin.
Topics: Aspirin; Chemoprevention; Coronary Thrombosis; Coronary Vessels; Drug Combinations; Fibrinolytic Age | 1997 |
Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fatal Outcome; Female; Humans; Middle Aged; Neutr | 1997 |
Ticlopidine induced agranulocytosis managed with granulocyte colony stimulating factor.
Topics: Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Platelet Aggregatio | 1998 |
Ticlopidine-induced severe neutropenia.
Topics: Aged; Aged, 80 and over; Fatal Outcome; Female; Humans; Male; Neutropenia; Platelet Aggregation Inhi | 1998 |
Bone marrow suppression and klebsiella pneumonia septicemia due to ticlopidine and successful treatment with filgrastim; a case report.
Topics: Biopsy, Needle; Bone Marrow; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating F | 1998 |
Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting.
Topics: Aged; Coronary Disease; Coronary Thrombosis; Fatal Outcome; Female; Humans; Male; Middle Aged; Neutr | 1999 |
Unstable angina pectoris.
Topics: Angina, Unstable; Clopidogrel; Humans; Neutropenia; Platelet Aggregation Inhibitors; Ticlopidine | 2000 |
Risk of neutropenia with clopidogrel.
Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Disease; Graft Occlusion, Vascular; Huma | 2000 |
Fibroelastoma of the mitral valve as a cause of transient ischemic stroke.
Topics: Adult; Female; Fibroma; Heart Neoplasms; Heart Valve Diseases; Humans; Ischemic Attack, Transient; M | 2001 |
[The use of a colony-stimulating factor (G-CSF) in iatrogenic neutropenias].
Topics: Aged; Captopril; Cefazolin; Colony-Stimulating Factors; Female; Filgrastim; Granulocyte Colony-Stimu | 1992 |
A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events.
Topics: Arteriosclerosis; Cerebrovascular Disorders; Diarrhea; Female; Humans; Male; Neutropenia; Randomized | 1992 |
Ticlopidine.
Topics: Cerebrovascular Disorders; Drug Administration Schedule; Female; Humans; Male; Monitoring, Physiolog | 1991 |
Thrombotic thrombocytopenic purpura related to ticlopidine.
Topics: Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ne | 1991 |
[Severe neutropenia caused by ticlopidine].
Topics: Female; Humans; Middle Aged; Neutropenia; Ticlopidine | 1991 |
Large trial finds ticlopidine superior to aspirin in preventing stroke.
Topics: Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Male; Neutropenia; Random All | 1989 |
[Mainly neutropenic pancytopenia caused by acute bone marrow depression during ticlopidine treatment].
Topics: Aged; Agranulocytosis; Anemia, Aplastic; Bone Marrow; Female; Humans; Neutropenia; Ticlopidine | 1987 |